Kodiak Sciences (KOD) CEO exercises 300,000 stock options into common shares

Rhea-AI Filing Summary

Kodiak Sciences Chairman and CEO Victor Perlroth exercised stock options for 300,000 shares of Common Stock at an exercise price of $1.0400 per share. These options were fully vested at the time of exercise. Following the transaction, he directly holds 2,395,538 shares of Common Stock. No open-market sales were reported in this filing, and the derivative position tied to this specific option grant has been fully converted into common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PERLROTH VICTOR

(Last) (First) (Middle)

1250 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kodiak Sciences Inc. [ KOD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/25/2026		M		300,000	A	$1.04	2,395,538	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.04	03/25/2026		M			300,000	(1)	06/22/2026	Common Stock	300,000	$0	0	D

Explanation of Responses:

1. The shares subject to this option are fully vested.

	/s/ David G. Peinsipp, Attorney-in-Fact for Victor Perlroth	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Kodiak Sciences (KOD) report for Victor Perlroth?

Kodiak Sciences reported that Chairman and CEO Victor Perlroth exercised stock options for 300,000 shares of Common Stock at $1.0400 per share. The transaction converts previously granted options into shares, without indicating any open-market sale in this filing.

How many Kodiak Sciences shares does Victor Perlroth hold after this Form 4?

After the reported transactions, Victor Perlroth directly holds 2,395,538 shares of Kodiak Sciences Common Stock. This reflects his position following the exercise of 300,000 stock options that were fully vested and converted into common shares on March 25, 2026.

Did Victor Perlroth buy or sell Kodiak Sciences (KOD) shares on the market?

The Form 4 shows no open-market purchases or sales. Instead, Victor Perlroth exercised 300,000 stock options at $1.0400 per share, converting a derivative award into Common Stock, with the resulting holdings recorded as 2,395,538 shares directly owned.

What was the nature of the derivative transaction reported for Kodiak Sciences?

The filing reports an option exercise classified as an exercise or conversion of a derivative security. A fully vested stock option covering 300,000 underlying shares of Common Stock was exercised at an exercise price of $1.0400, eliminating that option position and increasing direct share ownership.

Are the stock options exercised by Victor Perlroth in Kodiak Sciences fully vested?

Yes. A footnote states that the shares subject to this option are fully vested. This means the 300,000 options exercised at $1.0400 per share were already earned under the grant terms before being converted into Common Stock on March 25, 2026.

Does this Kodiak Sciences Form 4 show any remaining derivative holdings for Victor Perlroth?

The derivative summary in the data is empty, and the option entry shows zero shares following the transaction, indicating this specific 300,000-share option grant has been fully exercised, with no remaining derivative position from that grant reflected in this filing.